Tim Wehr is staff scientist at Bio-Rad Laboratories, Hercules, California. Direct correspondence about this column to Direct correspondence about this column to "Directions in Discovery," LCGC, Woodbridge Corporate Plaza, 485 Route 1 South, Building F, First Floor, Iselin, NJ 08830, e-mail lcgcedit@lcgcmag.com.
Quantitative Proteomics: Available Tools and Results of Collaborative Study
October 1st 2007Quantitative assessment of protein expression in biological systems in response to perturbations is an important element in the discovery and validation of biomarkers and drug targets. This can be a challenging task given the complexity and dynamic range of biological extracts. Many methods are currently in use to address protein quantification. This installment of "Directions in Discovery" reviews several of the more popular ones and reports on a collaborative study organized by the Association of Biomolecular Resource Facilities.
Top-Down versus Bottom-Up Approaches in Proteomics
September 1st 2006September 2006. Top-down and bottom-up are alternative strategies for protein identification and characterization by mass spectrometry. How do they fit into the world of proteomics? What are their implications for separation technology? These questions are addressed in this installment of "Directions in Discovery."
Capillary Electrophoresis in the Biopharmaceutical Industry: Part I
July 1st 2005Almost 40 years have passed since the concept of capillary electrophoresis (CE) was described by Hjertén (1) in 1967. It emerged as a viable analytical technique after the pioneering work of Jorgenson (2) in the early 1980s, and commercial instruments were first introduced at the end of that decade. It is appropriate at this time to survey the history of CE and to judge its success in the world of analytical instrumentation.
Chromatography Applications in Drug Discovery of Therapeutic Proteins
March 1st 2005In this month's installment of "Directions in Discovery," the authors discuss how, with the arrival of combinatorial libraries and high-throughput screening, pharmaceutical firms can develop new models of drug discovery that not only lessen the initial capital outlay involved in drug discovery, but also refine the discovery process.
Configuring HPLC Systems for LC–MS
April 1st 2000This month's "Directions in Discovery" looks at column and mobile-phase selection as well as system components and modification. Making the right choices among these parameters will help analysts get the most out of their liquid chromatography–mass spectrometry systems.